Intramuscular versus low‐dose intradermal hepatitis B vaccine: Assessment by humoral and cellular immune response to hepatitis B surface antigen

1987 ◽  
Vol 146 (5) ◽  
pp. 242-245 ◽  
Author(s):  
Ian H. Frazer ◽  
Bronwyn Jones ◽  
Ian R. Mackay ◽  
Mary Dimitrakakis
Vaccine ◽  
2008 ◽  
Vol 26 (48) ◽  
pp. 6064-6067 ◽  
Author(s):  
Yali Hu ◽  
Qiaozhen Wu ◽  
Biyun Xu ◽  
Zhenxian Zhou ◽  
Zhiqun Wang ◽  
...  

2009 ◽  
Vol 22 (2) ◽  
pp. 125-130 ◽  
Author(s):  
Teeraporn Chinchai ◽  
Chintana Chirathaworn ◽  
Kesmanee Praianantathavorn ◽  
Apiradee Theamboonlers ◽  
Yanee Hutagalung ◽  
...  

2006 ◽  
Vol 36 ◽  
pp. S167-S168
Author(s):  
A. Schumann ◽  
M. Fiedler ◽  
M. Lindemann ◽  
H. Grosse-Wilde ◽  
M. Roggendorf

2020 ◽  
Author(s):  
Weihong Lv ◽  
Tao Wei ◽  
Shanjuan Tan ◽  
Ling Li ◽  
Jijun Teng ◽  
...  

Abstract Background: Whether maternal anti-HBs acquired transplacentally plays a negative role in newborn infants’ immune response to hepatitis B vaccine (HepB Vac), it remains controversial and has not been paid enough attention.Methods: 267 BALB/c mice were bred. All mice were divided into two groups according to different doses of HepB Vac (2μg, 5μg) injected to mice. Each group was sub-divided into three subgroups according to different doses of hepatitis B immunoglobulin (HBIG) (50 IU, 25 IU, 0 IU) injected combined with the first dose of HepB Vac. Three doses of HepB Vac were administrated at 0 week, 4week and 8 week respectively. Antibodies against hepatitis B surface antigen (anti-HBs) were tested four weeks after the third dose of HepB Vac.Results: Among 267 mice, 40 were of low- and non-response to HepB Vac (anti-HBs<100 mIU/mL). Multivariate logistic regression analysis showed that rates of anti-HBs<100 mIU/mL were: 1.1%, 23.1% and 20.7% in groups of HBIG=0 IU(1), HBIG=25 IU(2) and HBIG=50 IU(3) respectively, p = 0.002, and among subgroups, (1) vs (3), RR= 0.032, 95% CI [0.004, 0.255], p = 0.001, (2) vs (3), RR= 1.359, 95% CI [0.588, 3.144], p = 0.473; 4.5% and 25.6% in groups of HepB Vac 5μg and 2μg, RR=0.093, 95% CI [0.035, 0.250], p <0.001; 6.1% and 23.7% in groups of intramuscular injection and hypodermic injection, RR=0.139, 95% CI [0.056, 0.346], p <0.001. The mean titers of anti-HBs (log10mIU/m) were on the decrease in turn in groups of HBIG= 0 IU, HBIG= 25 IU and HBIG= 50 IU, p <0.001.Conclusions: HBIG has a negative impact on both the rate of effective immune response and response level of anti-HBs, which preliminarily indicates maternal anti-HBs inhibits infants’ immune response to HepB Vac.


2006 ◽  
Vol 44 ◽  
pp. S189
Author(s):  
A. Schumann ◽  
M. Fiedler ◽  
M. Lindemann ◽  
H. Grosse-Wilde ◽  
M. Roggendorf

Pteridines ◽  
2018 ◽  
Vol 29 (1) ◽  
pp. 1-5
Author(s):  
Songül Ü Ünüvar ◽  
Hamza Aslanhan ◽  
Zübeyde Tanrıverdi ◽  
Fuat Karakuş

Abstract Hepatitis B is a life-threatening viral liver infection caused by the hepatitis B virus. Neopterin is regarded as an immunologic biomarker of several diseases related to activation of the cellular immune system. Hepatitis B infection is associated with increased production of cellular immune system markers. We aimed to investigate whether there is a relationship between hepatitis B surface antigen-positivity (HBsAg +) and neopterin to determine the role of neopterin in the early diagnosis of hepatitis B infections. Seventy-two HBsAg (+) patients with normal liver function tests and forty-three controls were included in the study. Neopterin levels were 17.6 ± 0.13 nmol/L in HBsAg (+) patients; and 9.12 ± 0.09 nmol/L in infection-free controls, respectively. Compared to the control group, a statistically significant increase (p < 0.001) in the serum neopterin levels of the patients was observed. No significant relationship was determined between neopterin levels and age/sex (both, p > 0.05). With overstimulation of interferon-gamma, the production of neopterin increases by monocytes/macrophages. Likewise with other diseases associated with an activated cellular immune system, this study shows that neopterin can be a predictive biomarker for persistent carriers of hepatitis B infection.


1988 ◽  
Vol 7 (1) ◽  
pp. 21-33 ◽  
Author(s):  
C. Ferrari ◽  
A. Penna ◽  
A. DegliAntoni ◽  
F. Fiaccadori

2008 ◽  
Vol 69 (2) ◽  
pp. 405-416 ◽  
Author(s):  
Olga Borges ◽  
Anabela Cordeiro-da-Silva ◽  
Joana Tavares ◽  
Nuno Santarém ◽  
Adriano de Sousa ◽  
...  

Author(s):  
Diky Mudhakir ◽  
Adik Ahmadi ◽  
Muhamad Insanu ◽  
Neny Nuraini

Objective: Oftentimes, the recombinant antigen for the use of vaccines is less immunogenic than live attenuated or inactive vaccines. Hence, a potent adjuvant is needed to enhance the immune response. Moreover, the role of vector design is also important to facilitate the improvement of the immune response. The aim of this research was to develop hepatitis B surface antigen (HBsAg)-loaded nanoparticles and Moringa oleifera aqueous leaf extracts as an adjuvant using chitosan polymer. Methods: Chitosan nanoparticles were prepared by the ionic gelation method using sodium tripolyphosphate as the cross-linking agent. A system was composed of chitosan core in which HBsAg and M. oleifera extracts were incorporated. The concentration of HBsAg used in this combination was 10 μg/ml, and the concentrations of extracts were 10, 50, and 100 μg/ml, respectively. In this study, three types of nanoparticles were produced: HBsAg-loaded nanoparticles, M. oleifera-loaded nanoparticles, and combination of HBsAg–M. oleifera-loaded nanoparticles. The nanoparticles formed were characterized by the particle size, HBsAg entrapment efficiency using sodium dodecyl sulfate polyacrylamide gel electrophoresis, and the entrapment efficiency of extracts using the total flavonoid method. Results: The results showed that the particle size was between 111 and 245 nm. The entrapment efficiency of HBsAg in the separate formula was 79%, while that in the combined formula was approximately 96–98%. Furthermore, the entrapment efficiency of the extracts in the separate formula was around 64–91%, while that in the combined formula was 55–82.5%. Particularly, HBsAg–M. oleifera-loaded chitosan nanoparticles with the extract concentrations of 50 μg/ml showed the highest entrapment efficiencies of HBsAg and M. oleifera extracts of approximately 98 and 82.5%, respectively. Conclusion: Collectively, the system has been successfully developed, so it is then plausible to determine the function of the devices to enhance the immune response in the future.


Sign in / Sign up

Export Citation Format

Share Document